Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• CAR-T therapy is highly effective against hematological malignancies like leukemia and myeloma.
• Significant barriers hinder CAR-T efficacy in solid tumors, including antigen scarcity, immune suppression, and poor infiltration.
• Current limitations restrict CAR-T cell function, leading to immune escape and potential toxicity.

Purpose of the Study:

• To review next-generation engineering strategies for CAR-T cell therapy in solid tumors.
• To discuss methods for overcoming biological and structural barriers limiting CAR-T efficacy.
• To guide the development of safer and more effective CAR-T platforms for solid tumors.

Main Methods:

• Review of current literature on CAR-T cell engineering for solid tumors.
• Analysis of biological and structural challenges in solid tumor microenvironments.
• Discussion of novel engineering approaches, including logic-gated receptors, multi-antigen targeting, and in vivo engineering.

Main Results:

• Diverse engineering strategies are being developed to enhance CAR-T cell performance in solid tumors.
• Approaches focus on improving tumor recognition, trafficking, persistence, and overcoming immunosuppression.
• New strategies aim to mitigate on-target, off-tumor toxicities and promote durable responses.

Conclusions:

• Next-generation CAR-T engineering holds potential to overcome solid tumor barriers.
• Innovative strategies are crucial for advancing CAR-T therapy towards broader clinical application in solid tumors.
• Further research and development are needed to optimize safety and efficacy for solid tumor treatment.